经皮射频消融治疗临床 I 期不可手术的非小细胞肺癌患者。
Percutaneous radiofrequency ablation for medically inoperable patients with clinical stage I non-small cell lung cancer.
机构信息
Department of Thoracic Surgery, Xuanwu Hospital of Capital Medical University Beijing, China.
出版信息
Thorac Cancer. 2015 May;6(3):327-33. doi: 10.1111/1759-7714.12200. Epub 2014 Dec 22.
BACKGROUND
A retrospective evaluation of percutaneous radiofrequency ablation (RFA) in medically inoperable patients with clinical stage I non-small cell lung cancer (NSCLC).
METHODS
Between 2008 and 2014, 29 medically inoperable patients with clinical stage I NSCLC underwent percutaneous RFA. We evaluated the feasibility, safety, and effectiveness.
RESULTS
There were 18 men and 11 women with a median age of 78.0 years (range 56-85), mean 76.0 years. No procedure-related deaths occurred in any of the 33 ablation procedures. The mean follow-up was 25 months. The incidence of local tumor progression was 21.0% at 25 months of median time to progression after the initial RFA. The mean overall survival (OS) was 57 months (95% confidence interval (CI) 44-70 months). The mean cancer-specific survival CSS was 63 months (95% CI 50-75 months). OS was 90.5% ± 6.4% at one year, 76.4% ± 10.7% at two, and 65.5% ± 13.6% at three years. CSS was 95.2% ± 4.6% at one, 86.6% ± 9.3% at two, and 74.2% ± 13.9% at three years in all patients. The survival for stage IA and IB cancers were 87.5% and 92.3% at one, 87.5% and 73.4% at two, and 87.5% and 58.7% at three years, respectively. Survival rates were not significantly different between the two groups (P = 0.596), with mean survival times of 65 (95% CI: 51-79 months) and 55 months (95% CI: 38-71 months), respectively.
CONCLUSION
Percutaneous RFA is a safe, feasible, and effective procedure in medically inoperable clinical stage I NSCLC patients.
背景
回顾性评估经皮射频消融（RFA）在临床 I 期非小细胞肺癌（NSCLC）不能手术的患者中的应用。
方法
2008 年至 2014 年，29 例临床 I 期 NSCLC 不能手术的患者接受了经皮 RFA。我们评估了其可行性、安全性和有效性。
结果
33 例消融术中无 1 例与操作相关的死亡。中位随访时间为 25 个月。在初始 RFA 后中位进展时间 25 个月时，局部肿瘤进展的发生率为 21.0%。平均总生存期（OS）为 57 个月（95%置信区间 44-70 个月）。平均癌症特异性生存期（CSS）为 63 个月（95%置信区间 50-75 个月）。OS 为 1 年时 90.5%±6.4%，2 年时 76.4%±10.7%，3 年时 65.5%±13.6%。CSS 为 1 年时 95.2%±4.6%，2 年时 86.6%±9.3%，3 年时 74.2%±13.9%。IA 期和 IB 期癌症的生存情况分别为 1 年时 87.5%和 92.3%，2 年时 87.5%和 73.4%，3 年时 87.5%和 58.7%。两组患者的生存率无统计学差异（P=0.596），平均生存时间分别为 65（95%CI：51-79 个月）和 55 个月（95%CI：38-71 个月）。
结论
经皮 RFA 是一种安全、可行、有效的治疗不能手术的临床 I 期 NSCLC 患者的方法。
Zotero 插件